Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

49
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
49
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

34
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
34
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

49
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
49
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

948
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
948
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

33
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
33
Varicose Veins I: Introduction01:26

Varicose Veins I: Introduction

31
Varicose veins, or varicosities, are abnormally dilated and twisted superficial veins caused by venous valve incompetence. This condition commonly affects the lower extremities, especially the saphenous veins, due to the higher pressure from prolonged standing and walking. However, varicosities can also occur in other areas, such as the esophagus, vulva, spermatic cords, and anorectal region.Etiology and typesPrimary varicose veins, often idiopathic, are more common in women due to inherent...
31

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Frequency <i>PPM1D</i> Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

Cancers·2026
Same author

From Prediction to Action: Why Bleeding Risk in Cardiac Surgery Still Eludes Us in the Era of Artificial Intelligence.

Anesthesiology·2026
Same author

Influence of <i>PPM1D</i> Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

Biomedicines·2026
Same author

Inconsistency of the FIB-4 Score in Hospitalized Patients.

The journal of applied laboratory medicine·2026
Same author

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
Same author

Long-Term Antidepressant Use and Dementia Risk: A Propensity Score-Matched Study of Swiss Older Adults, with an Anticholinergic-Specific Analysis.

Drugs - real world outcomes·2026

Related Experiment Video

Updated: Sep 26, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Current Knowledge on Factor V Leiden Mutation as a Risk Factor for Recurrent Venous Thromboembolism: A Systematic

Daria Eppenberger1, Henning Nilius1, Betsy Anagnostelis2

  • 1Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Frontiers in Cardiovascular Medicine
|April 25, 2022
PubMed
Summary

The Factor V Leiden (FVL) mutation increases the risk of recurrent venous thromboembolism (VTE) by 46%. However, FVL plays a minor role in overall VTE recurrence risk assessment when considering established risk factors.

Keywords:
heterozygous factor V Leiden mutationprospective cohort studiesrecurrent venous thromboembolismrisk factorssystematic review

More Related Videos

Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
04:34

Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis

Published on: June 15, 2011

18.5K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.7K

Related Experiment Videos

Last Updated: Sep 26, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
04:34

Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis

Published on: June 15, 2011

18.5K
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
04:40

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

2.7K

Area of Science:

  • Hematology
  • Genetics
  • Epidemiology

Background:

  • Thrombophilia screening is common, but the VTE recurrence risk associated with common defects like FVL is not fully understood.
  • Assessing the precise contribution of genetic factors to VTE recurrence is crucial for clinical risk stratification.

Purpose of the Study:

  • To systematically review and meta-analyze observational studies on the association between heterozygous Factor V Leiden (FVL) mutation and recurrent VTE.
  • To quantify the pooled relative risk (RR) of VTE recurrence in patients with and without the FVL mutation.

Main Methods:

  • A comprehensive search of MEDLINE and EMBASE databases was conducted for prospective cohort studies.
  • Data from 24 high-quality studies (13,571 patients) were extracted and analyzed using a random-effects model.
  • Methodological quality was assessed using the Newcastle-Ottawa Scale.

Main Results:

  • Heterozygous FVL mutation was present in 21% of the included patients.
  • The pooled relative risk (RR) for recurrent VTE in patients with heterozygous FVL mutation was 1.46 (95% CI: 1.31, 1.64).
  • This increased risk was consistent across various subgroups.

Conclusions:

  • Heterozygous FVL mutation is associated with a 46% increased risk of recurrent VTE.
  • Despite this increase, FVL mutation has a marginal impact on the overall risk assessment for recurrent VTE when established risk factors are considered.